Form 4: Cytokinetics EVP Malik Reports Stock Withholding for Tax Obligations
SEC Form 4 Filing
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reports the withholding of shares to cover tax obligations related to vesting Restricted Stock Units.
Summary
- Fady Ibraham Malik, an Executive Vice President at Cytokinetics, filed a Form 4 indicating changes in beneficial ownership of the company's stock.
- The report details the withholding of Cytokinetics common stock to satisfy tax obligations related to the vesting of Restricted Stock Units.
- On March 4, 2024, 9,630 shares were withheld at a price of $67.68.
- On March 6, 2024, 8,109 shares were withheld at a price of $66.88.
- Following these transactions, Malik directly owns 121,234 shares of Cytokinetics common stock.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction (stock withholding for tax purposes) and doesn't indicate any significant positive or negative developments for the company. It's a neutral event from an investment perspective.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates standard tax-related stock withholding, a common practice among executives with equity compensation.
Key Dates
| Date | Description |
|---|---|
| 03/04/2024 | 9,630 shares of common stock withheld at $67.68. |
| 03/06/2024 | 8,109 shares of common stock withheld at $66.88. |
| 03/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.